This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Articles|March 19, 2020
Lonza Pharma & Biotech
Author(s)Lonza Pharma & Biotech
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable biotech and pharma companies to bring large and small-molecule medicines to patients in need.
At Lonza Pharma & Biotech, we provide contract development and manufacturing services that enable biotech and pharma companies to bring large and small-molecule medicines to patients in need. From drug substance to the final drug product, our solutions feature concept to commercial capabilities to simplify your outsourcing experience and to provide a reliable outcome when you expect it. Together, we can bring your next medicine to life.
Lonza Pharma & Biotech
Muechensteinstrasse 38 4002 Basel, Switzerland
tel. + 41.61.316 8111
[email protected]
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.